Page last updated: 2024-10-24

candesartan and Leukemia, Myeloid, Acute

candesartan has been researched along with Leukemia, Myeloid, Acute in 1 studies

candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.

Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Ramzy, S1
Abdelazim, AH1
Shahin, M1

Other Studies

1 other study available for candesartan and Leukemia, Myeloid, Acute

ArticleYear
Quantitative Analysis of Two Pharmaceutical Combinations Containing Amlodipine with Either Bisoprolol or Candesartan Using Different UV Spectrophotometric Methods.
    Journal of AOAC International, 2022, Jun-29, Volume: 105, Issue:4

    Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Bisoprolol; Humans; Leukemi

2022